Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 15, 2022
Lead Product(s) : Denosumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INTP5
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 10, 2019
Lead Product(s) : INTP5
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INTP5
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 10, 2019
Lead Product(s) : INTP5
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Intas Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Ayana Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 24, 2018
Lead Product(s) : Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Ayana Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable